Medtronic (MDT) Stock Forecast & Price Target

Medtronic is well-positioned for potential upside in their stock with recent sales, acquisitions, and a strong product pipeline, but potential obstacles such as slower growth and reliance on specific business segments should be monitored. While the company's strong growth prospects in the cardiac and vascular sector make it a compelling investment, it is important for investors to pay attention to potential disruptions in TAVR volumes and the pace of margin expansion to accurately evaluate its performance and valuation. Additionally, the company should also be compared to other promising companies in the medical industry, such as Dexcom, Abbott Laboratories, and Boston Scientific, to determine the best investment opportunities.

Medtronic is facing various challenges, particularly in the cardiovascular and diabetes segments, that could hinder its future growth potential and ultimately impact its financial performance. Additionally, competition in the medical device industry is fierce and Medtronic's revenue growth could slow down if competitors gain market share in certain product categories. The company's decision to separate its diabetes business could also have mixed results, with potential upside in earnings but also a potential drag on its overall growth. Overall, while Medtronic has some strengths in its portfolio, its current financials and outlook may not justify its current stock price, leading to the negative outlook.